Diabetes drug Bydureon gains positive feedback from EU agency

04/17/2011 | Reuters

The European Medicines Agency said Eli Lilly and Co. and Amylin Pharmaceuticals' once-weekly injectable Bydureon is suitable for adults with type 2 diabetes. Bydureon, a potential rival to Novo Nordisk's once-daily treatment Victoza, was rejected by the FDA last year. "While we believe the EU decision is completely separate from the FDA's decision ... we believe the EU's decision suggests they view Bydureon safe enough for use and the U.S. may likely follow," wrote analyst Robyn Karnauskas of Deutsche Bank.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Chief Financial Officer
B. E. Smith
Miramar, FL
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA